Evotec, Halozyme

Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...
Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall ...
Halozyme Therapeutics Inc. (HALO) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of ...
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...
Triton Partners is considering a takeover bid for Germany’s Evotec SE, according to people familiar with the matter, after the private equity firm emerged as one of the drug developer’s ...
Evotec price target lowered to EUR 11.60 from EUR 12 at RBC Capital Evotec rallies after Bloomberg says Triton weighing takeover bid Evotec Reports Strategic Growth Amidst Revenue Challenges ...
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...